Exfoliation glaucoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:32:35 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Exfoliation glaucoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Glaucoma Treatment: Comparing Brimonidine, Pilocarpine Nitrate, and Brinzolamide in Patients with Newly Diagnosed Open-Angle Glaucoma https://clinicaltrials.eu/trial/study-on-glaucoma-treatment-comparing-brimonidine-pilocarpine-nitrate-and-brinzolamide-in-patients-with-newly-diagnosed-open-angle-glaucoma/ Wed, 29 Apr 2026 14:29:22 +0000 https://clinicaltrials.eu/trial/study-on-glaucoma-treatment-comparing-brimonidine-pilocarpine-nitrate-and-brinzolamide-in-patients-with-newly-diagnosed-open-angle-glaucoma/ This clinical trial is focused on studying the progression of glaucoma, specifically open-angle glaucoma and PEX glaucoma. Glaucoma is a condition that affects the eyes and can lead to vision loss due to damage to the optic nerve. The study aims to compare two different treatment approaches for patients who have been newly diagnosed with this condition. The treatments being tested include a single medication approach and a combination of medications, which may include additional treatments like laser therapy. The medications involved in this study are brimonidine, pilocarpine nitrate, brinzolamide, timolol maleate, latanoprost, betaxolol, bimatoprost, dorzolamide hydrochloride, travoprost, and tafluprost. Some of these medications may be used in combination to enhance their effectiveness.

The purpose of the study is to observe and compare how quickly the disease progresses in patients receiving different types of treatment. Participants will be randomly assigned to either the intensive treatment group or the conventional treatment group. The study will monitor the rate of vision loss and any changes in the condition over time. This will help determine which treatment approach is more effective in slowing down the progression of glaucoma. The study will also consider the quality of life of the participants and how well they adhere to the treatment plan.

Participants in the study will receive treatment for a period of up to 120 days, with regular follow-ups to assess their condition. The study will continue to collect data on the participants’ eye health and vision changes. This information will be used to better understand the effectiveness of the treatments and to improve future care for individuals with glaucoma. The study is expected to conclude by the end of 2027.

]]> Study on the Effectiveness of Citicoline Eye Drops for Visual Field Preservation in Patients with Open Angle Glaucoma https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-citicoline-eye-drops-for-visual-field-preservation-in-patients-with-open-angle-glaucoma/ Wed, 29 Apr 2026 14:23:53 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-citicoline-eye-drops-for-visual-field-preservation-in-patients-with-open-angle-glaucoma/ This clinical trial is focused on studying the effects of a treatment for glaucoma, a condition that affects the eyes and can lead to vision loss. The treatment being tested is citicoline eye drops, which are being compared to placebo eye drops. The main goal of the study is to determine if citicoline eye drops can better preserve the visual field, which is the area a person can see, in patients with open-angle glaucoma, a common type of glaucoma where the drainage angle for eye fluid remains open.

Participants in the study will receive either the citicoline eye drops or placebo eye drops. The study will last for a period of three years, during which the participants’ eye health and vision will be monitored regularly. The study aims to see if there is a difference in how the vision changes over time between those using citicoline and those using placebo. The researchers will also look at changes in the thickness of certain layers of the retina, the light-sensitive tissue at the back of the eye, using a method called Optical Coherence Tomography (OCT).

This study is important for understanding whether citicoline eye drops can help slow down the progression of vision loss in people with open-angle glaucoma. By comparing the effects of citicoline to placebo, researchers hope to find a more effective way to manage this eye condition and improve the quality of life for those affected by it.

]]>